ICH E6(R3)
Good Clinical Practice for clinical trials involving human participants
Standard Introduction
ICH E6(R3) is the current harmonised Good Clinical Practice guideline for planning, initiating, conducting, recording, overseeing, evaluating, analysing and reporting clinical trials involving human participants. Its Principles and Annex 1 reached ICH Step 4 on 6 January 2025; Annex 2 reached Step 4 on 3 June 2026.
The revision strengthens quality by design, proportionate risk management, participant protection, sponsor and investigator accountability, data governance and fit-for-purpose systems. Annex 2 adds considerations for decentralised and pragmatic elements, digital health technologies and real-world data. Legal effect and dates depend on each regulator's adoption.
Participant Protection
Places the rights, safety and well-being of trial participants ahead of scientific and societal interests, supported by informed consent and independent ethical review.
Quality by Design
Requires trial quality to be designed around factors critical to participant protection and reliable results, using proportionate risk identification, control, review and reporting.
Modern Trial Methods
Annex 2 applies GCP considerations to decentralised elements, pragmatic trials, digital health technologies and real-world data without endorsing one methodology.
list_alt Core ICH E6(R3) Expectations
- Ethical conduct and independent IRB/IEC review
- Voluntary, informed and documented participant consent
- Clear sponsor, investigator and service-provider responsibilities
- Quality by design and proportionate risk-based quality management
- Reliable, traceable and protected trial data and metadata
- Fit-for-purpose computerised systems and validated data processes
- Safety assessment, reporting and investigational-product control
- Essential records sufficient to reconstruct and evaluate trial conduct
Who Needs to Comply?
Sponsors, investigators, trial sites, contract research organizations, laboratories, technology and data service providers, institutional review boards or independent ethics committees, and teams designing, conducting, monitoring, analysing or reporting interventional clinical trials intended for medicines-regulatory use. Each organization must also follow the laws and regulator implementation applicable in every trial country.
Key Requirements
Ethics and Informed Consent
Obtain documented IRB/IEC approval before trial initiation, maintain continuing ethical oversight, and use a consent process that supports participant understanding and reflects the trial design, risks, data use and applicable law.
Defined Responsibilities and Oversight
Document responsibilities for sponsors, investigators, institutions, committees and service providers. Transferring activities does not remove the sponsor's responsibility for appropriate oversight or the investigator's responsibility for delegated trial activities.
Quality and Risk Management
Identify factors critical to trial quality, evaluate risks to those factors, implement proportionate controls, communicate them, review effectiveness and report important quality issues and remedial actions.
Data Governance and Computerised Systems
Protect confidentiality and blinding; define data ownership, access, collection, transfer, review and correction; maintain secure audit trails and metadata; and ensure systems and processes are fit for purpose throughout the data lifecycle.
Protocol, Safety and Essential Records
Use an operationally feasible protocol, manage deviations and amendments, assess and report safety information, control investigational products, and retain essential records that allow reconstruction of the trial and evaluation of GCP compliance and result reliability.
Annex 2 Methodologies
For decentralised, pragmatic or real-world-data elements, tailor participant protection, consent, investigator oversight, data provenance, privacy, remote collection, technology, safety and service-provider controls to the methodology and local regulatory requirements.
Implementation Roadmap
Map adoption, roles, and trial scope
For each country and protocol, confirm the applicable clinical-trial law, regulator adoption of E6(R3), ethics requirements, and effective dates. Map sponsors, investigators, sites, IRB/IEC bodies, committees, laboratories, technology providers, data sources, and transferred activities, while retaining accountable oversight.
Design quality into the protocol
Identify factors critical to participant protection and reliable results. Make the protocol operationally feasible, involve relevant patients or clinical stakeholders where appropriate, define endpoints and data provenance, and scale controls to the probability, detectability, and impact of errors that matter.
Build controls, systems, and evidence
Update agreements, delegation records, consent materials, monitoring, safety, data management, validation, statistics, investigational-product controls, computerised-system governance, access, audit trails, service-provider oversight, and the essential-record plan. Test workflows before first participant enrollment.
Operate, review, and retain
Monitor critical-to-quality factors, emerging risks, deviations, safety, data integrity, provider performance, and participant burden. Review whether controls remain effective, document important quality issues and remediation, report transparently, and retain accessible records and metadata for the required period.
Compliance Checklist
checklist Applicability and governance
checklist Participants, protocol, and safety
checklist Quality, data, and systems
checklist Annex 2 and modern methods
ICH E6(R3) Structure and Adoption
The harmonised documents work together, while legal effect and effective dates are determined by each regulator.
| Reference | Primary scope | ICH status | Implementation significance |
|---|---|---|---|
| Principles | Ethical, scientific, and quality foundation for clinical trials | Step 4 within E6(R3) | Apply across trial types and interpret Annexes consistently |
| Annex 1 | Detailed application to interventional clinical trials | Step 4 on 6 Jan 2025 | Core responsibilities, consent, quality, data, systems, safety, protocol, and records |
| Annex 2 | Decentralised, pragmatic, and real-world-data methodologies | Step 4 on 3 Jun 2026 | Additional controls for evolving designs, technologies, locations, and data sources |
| EU implementation | EMA/CHMP regional adoption | Step 5 | Annex 1 effective 23 Jul 2025; Annex 2 effective 15 Jan 2027 |
| U.S. implementation | FDA final guidance | Final Level 1 guidance issued Sept 2025 | Nonbinding recommendations used with applicable U.S. statutes and regulations |
Common Misconceptions
ICH Step 4 creates one globally binding effective date.
Step 4 finalizes the harmonised ICH text for regulatory adoption. Each jurisdiction determines how and when it is implemented.
Annex 2 replaces Annex 1 for decentralised trials.
Annex 2 must be read with the Principles and Annex 1 and adds methodology-specific considerations.
A vendor contract transfers the sponsor's accountability for trial quality.
Activities may be transferred, but the sponsor retains responsibility for appropriate oversight of transferred activities and service providers.
Risk-based monitoring means fewer controls and less evidence.
It means controls and evidence are focused proportionately on risks that matter to participants and result reliability, with documented review and escalation.
Penalties & Enforcement
ICH E6(R3) is a harmonised guideline, not a certification standard and not a stand-alone penal law. Consequences arise through applicable clinical-trial law, medicines regulation, ethics approval, contracts and regulator adoption. Failures can lead to inspection findings, corrective action, trial suspension, rejection of data, refusal or delay of marketing authorization, investigator restrictions, civil or criminal exposure, and harm to participants. The exact consequence is jurisdiction-specific.
Frequently Asked Questions
What is ICH E6(R3)?
expand_more
ICH E6(R3) is the current ICH Good Clinical Practice guideline for trials involving human participants. It provides principles and detailed expectations intended to protect participants and support reliable results that regulators can assess across ICH regions. It is implemented through each regulator's own process rather than becoming law globally on one date.
When did ICH E6(R3) become final?
expand_more
The Principles and Annex 1 reached ICH Step 4 on 6 January 2025. Annex 2 reached Step 4 on 3 June 2026, and ICH issued a consolidated document in June 2026. Step 4 means the final harmonised text is recommended for adoption by ICH regulatory members; organizations must still check regional implementation.
When does E6(R3) apply in the European Union?
expand_more
The Principles and Annex 1 have applied in the EU since 23 July 2025. EMA states that Annex 2 and the consolidated guideline become effective on 15 January 2027. That EU date should not be copied to other jurisdictions without checking their regulator.
Has the FDA adopted ICH E6(R3)?
expand_more
FDA issued E6(R3) as final Level 1 guidance in September 2025. FDA guidance describes the agency's current thinking and contains nonbinding recommendations; binding obligations continue to arise from applicable U.S. statutes and regulations. FDA separately identifies its Annex 2 work, so users should check the current FDA guidance page for status.
What is the difference between Annex 1 and Annex 2?
expand_more
Annex 1 explains how the GCP principles apply to interventional clinical trials generally. Annex 2 adds considerations for trials using decentralised or pragmatic elements and real-world data. Annex 2 supplements the Principles and Annex 1; it does not replace them or endorse a particular technology or design.
Does ICH E6(R3) require 100 percent source-data verification?
expand_more
No. E6(R3) supports proportionate, risk-based quality management and monitoring focused on factors critical to participant protection and reliable results. The monitoring strategy still needs a documented rationale, appropriate controls, effective issue detection, and compliance with applicable local requirements.
Can an organization be certified to ICH E6(R3)?
expand_more
ICH E6(R3) is not an organizational certification standard and ICH does not certify sponsors, sites, investigators, or service providers. Compliance is evaluated through ethics oversight, sponsor oversight, audits, regulatory inspections, submission review, and any applicable national enforcement process.
Official Documentation
Official PDF for ICH E6(R3)
Official publication or summary for ICH E6(R3)
Official online resource
International Council for Harmonisation (ICH) guidance and reference material
Implementation toolkit
Templates, guidance, or companion resources for ICH E6(R3)